ALDX Stock Catalyst: Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap

Sep 28, 2026 · 4:33pm ET

The company plans to address the FDA's Complete Response Letter for dry eye disease treatment.

Max move

+25.0%

High of day $1.45

Sparker timei

4:33pm ET

ALDX · Sep 28, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced on September 29, 2026, its intent to submit a formal dispute resolution request to the FDA regarding Reproxalap for the treatment of dry eye disease. The decision follows the FDA's issuance of a Complete Response Letter.

The company disclosed this development in an 8-K filing available at https://www.sec.gov/Archives/edgar/data/1341235/000119312526405954/0001193125-26-405954-index.htm.

As of the latest data, Aldeyra Therapeutics has a free float of 52,675,373 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ALDX sparks.

Download Sniper App →

Catch the next ALDX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →

Every Second Counts.Don't Trade Without a Real-Time sparker alert.

ALDX Stock Catalyst: Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap

ALDX · Sep 28, 2026

ALDX · Sep 28, 2026

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.